Abstract: A large number of IL-1 protein sequences have become available recently from a range of vertebrate species and especially from bony fish. However, 3D structures are still only known for mammalian IL-1. In this review, we use a multiple sequence alignment of all published non-mammalian vertebrate IL-1β proteins to locate the structurally important residues critical for maintaining the β-trefoil fold and we investigate the degree to which functionally important residues involved in receptor binding are conserved across vertebrate species. We find that although there is a high level of variability of positions involved in receptor binding, the mode of binding and overall shape of the ligand-receptor complex is probably maintained. This implies that each species has evolved its own unique interleukin-1 signalling system through ligand-receptor co-evolution. Nonetheless, the IL-1β processing mechanism in non-mammalian vertebrates remains unclear because, with the exception of three bony fish, all non-mammalian IL-1β sequences discovered so far lack an ICE (Interleukin Converting Enzyme) cut site. The IL-1 system has become an important drug target because of its significance in inflammatory diseases. Research on peptides derived from IL-1β has identified peptides that possess agonist activity in humans and in trout, and peptides with antagonist activity. The agonist peptides map to two distinct loop regions of IL-1β that are known to interact with the flexible domain III of the corresponding receptor. Further analysis of the IL-1 system may prove useful in engineering IL-1 with improved features and in suggesting new avenues for therapeutic intervention.
INTRODUCTION
Interleukin-1 (IL-1) is a cytokine which exhibits pleiotropic functions in a variety of cells of the immune system e.g. B-cells, T-cells, monocytes, neutrophils and fibroblasts [1] , and it plays a pivotal role in the modulation of immune and inflammatory responses. There are currently ten known members in the IL-1 family, which recently have been assigned new names using the stem "Interleukin-1 Family-" (IL-1F). The extensively researched IL-1α, IL-1β, IL-1RA, IL-18 are now known as IL-1F1, IL-1F2, IL-1F3 and IL-1F4, respectively. However, in this review we will continue to use the more familiar older naming convention. IL-1α, IL-1β and IL-18 function as receptor agonists, while IL-1RA is a naturally occurring antagonist. The newer members, IL-1F5 -IL-1F10 were identified from sequence similarity to the known members of the family, which ranges from 11% identity (human IL-1F8 and IL-18) to 42% (human IL-1F5 and IL-1RA) [2] . Their role in disease is currently under investigation.
A common feature of the IL-1 family members is that they all adopt a β-trefoil fold despite their low sequence similarity. A large number of IL-1 protein sequences have become available recently from a range of vertebrate species and especially from bony fish, allowing greater insight into the evolution of this key player of the immune system. However, structural information is currently limited to mammalian IL-1, with structures having been deposited in the PDB [3] only for human IL-1α, IL-1β, IL-1RA and murine IL-1β.
In this review, we locate in all published non-mammalian vertebrate IL-1β proteins the structurally important residues critical for maintaining the β-trefoil fold [4] , [5] , and we examine the relation and degree of their sequence similarity. IL-1β peptides derived from human [6] and trout [7] can function as agonists, thus indicating the significance of certain regions of the protein in exerting its biological activity. Here, based on a multiple sequence alignment with human IL-1β, we identify and investigate the degree to which functionally important residues involved in receptor binding are conserved across vertebrate species.
We use a multiple sequence alignment of vertebrate IL-1β and published mutation studies to examine how vertebrate IL-1β binds to its receptor, how this interaction has evolved, and which regions of the molecule define its agonist activity and mechanism of action. We find that although there is a high level of variability of positions involved in receptor binding, the mode of binding and overall shape of the ligand-receptor complex is probably maintained. On the other hand, we find that the characteristics of those residues that are important for the fold are well conserved.
Medical Uses of IL-1 Family Members
The proinflammatory properties of IL-1 are exerted by production of prostaglandin-E2 (PGE2), platelet activating factor and nitric oxide (NO), through the activation of cyclooxygenase type 2 (COX-2), type 2 phospholipase A and inducible nitric oxide synthase (iNOS) [8] . IL-1 also induces the production of adhesion molecules, other cytokines, metalloproteinases and growth factors [2] , and therefore plays a profound role in human inflammatory disease. For this reason, control of its activity has been the focus of pharmacological research. Today, recombinant IL-1RA has been approved for treatment of rheumatoid arthritis (RA) in USA, Canada and Europe. Currently, other drug candidates aiming to antagonise IL-1 function are in clinical development, and are discussed below. Ultimately, the identification of structurally and functionally important regions on IL-1 through evolutionary studies should provide further clues to facilitate the design of new pharmaceuticals with modified and/or improved activity.
There are many excellent reviews on the IL-1 family. For example, Dinarello [9] gives an extensive review of the role of IL-1 in haematopoiesis, atherosclerosis, leukaemia and cancer. Dinarello [1] describes the members of the IL-1 family, its agonists, antagonists, and receptors, as well as the role of Interleukin-1 Converting Enzyme (ICE). Regulation of IL-1 is also discussed. The crystal structures of the IL-1RA/IL-1RI and IL-1β/IL-1RI complexes [10] provide structural insights on ligand-receptor interactions, and the IL-1RA "trigger region" is described, as well as the association of the complex with IL-1RAcP; IL-1 activating pathways are also considered. Bird et al. [11] studied the evolution of IL-1β using available vertebrate sequences and analysed their processing because there is no clear ICE cut site in nonmammalian sequences. Extensive information on gene organisation, expression and regulation is also given. The recent 4 th edition of "The Cytokine Handbook" [12] provides an encyclopaedic coverage of the molecules that induce and regulate immune responses with an emphasis on their clinical application. Dinarello [8] , Kumar [2] , Arend and Evans [13] , and Okamura et al. [14] , give extensive information on IL-1 family members, their structures, expression, regulation and signal transduction.
THE INTERLEUKIN-1 FAMILY OF PROTEINS
Each of the interleukins IL-1α, IL-1β and IL-1RA bind to the IL-1 receptor (IL-1R or CD121a). There are two types of IL-1R, type I and II. Both possess three extra-cellular immunoglobulin-like (Ig-like) domains, two of which are tightly positioned together while the third is connected via a flexible linker. The type I receptor also has a hydrophobic transmembrane region and a cytoplasmic domain that contains a Toll-like region presumably involved in signalling (human: 213 residues), while in the type II receptor the tail is very short (human: 29 residues) and non-functional, and is thus incapable of transducing a signal. IL-1RII acts as a sink for IL-1β and is known as a "decoy" receptor [1] .
Upon binding, the three Ig-like domains of IL-1R wrap around the ligand. Mutagenesis studies have shown that binding of IL-1 to IL-1R is not sufficient for cell activation. Association of another protein, the IL-1R accessory protein (IL-1RAcP) with the IL-1/IL-1R complex is required [15] . IL-1RAcP is homologous and structurally similar to IL-1R. On complex formation, the cytoplasmic domains of IL1RAcP and IL-1RI interact and initiate signalling [16] . The IL-1 signalling cascade involves the TRAF6 and IRAK protein kinases leading to the activation of transcription factors such as NFκB and AP1, which activate genes involved in immune and inflammatory responses [10] . When IL-1RA binds to IL-1R, no tertiary complex with IL-1RAcP is formed and so signalling does not occur.
IL-1α, IL-1β, IL-18 and IL-1RA
IL-1α and IL-1β are expressed as 30kDa precursors, which are proteolytically processed into either a 17.5kDa protein for mature IL-1α or a 17.3kDa molecule for IL-1β; both lack a signal peptide. IL-1α is capable of binding to the IL-1 receptor in its precursor form with similar affinity to the mature peptide [9] . It is processed by membrane-bound cysteine proteases known as calpains, but upon cell death it is also released into the extracellular space where it is cleaved by extracellular proteases. IL-1β is not functional in its precursor form. In mammals, release of mature IL-1β requires processing by ICE, which cleaves the Asp116-Ala117 peptide bond. ICE is a member of a family termed caspases, since they cleave after an Asp residue. Nonetheless, a variety of other enzymes such as elastase, trypsin, chymotrypsin and granzyme A can also proteolytically cleave the precursor molecules to produce a functional mature peptide [17] , [18] . Both IL-1α and IL-1β elicit similar biological effects, but it has been reported recently that IL-1β, and not IL-1α, is capable of inducing an antibody mediated immune response [19] .
In a similar fashion, ICE also processes pro-IL-18 into the mature functional peptide [20] . In humans, IL-18 receptor (IL-18R) is composed of two chains (IL-18α and IL-18β) and belongs to the same IL-1R Toll-like receptor family, as does IL-1R [21] . IL-18α, previously known as IL-1Rrp, is the ligand binding subunit, while IL-18Rβ, also named IL1RAcPL, is the signalling component [22] .
A unique feature of the IL-1 system is the presence of a naturally occurring receptor antagonist (IL-1RA). IL-1RA binds to the receptor in a similar manner to IL-1α and IL-1β, but it does not initiate signalling. The sequence of human IL-1RA is 26% similar to that of IL-1β and 19% to IL-1α. In humans, alternative transcriptional and translational mechanisms give rise to multiple IL-1RA isoforms, one secretory (s) IL-1RA which has a 25-residue signal peptide that allows extracellular secretion and three intracellular (ic) isoforms that lack a signal peptide. IL-1RA has certain structural differences, i.e. deletions, compared to its agonist counterparts that conformationally allow only partial interaction with the receptor. The complex formed fails to muster IL1AcP for binding and subsequent activation.
IL-1F5 -F10
The recently identified members IL-1F5 -F10 exhibit 20-42% sequence identity to IL-1RA. All except IL-1F7 lack a signal peptide or a propeptide sequence. Receptors are known for some of them. For example, IL-1F9 has been shown to bind IL-1Rrp2 (IL-1R6), another member of the IL-1R Toll-like receptor family, and activate NFκB. IL-1F5 binds to the same receptor as IL-1F9 and acts as an antagonist [23] . IL-1F7, which contains a putative caspase cut site, binds to IL-18Rα [24] , while IL-1F10 complexes to IL-1RI with affinities similar to IL-1β and IL-1RA [25] . It is unclear if IL-1F7 and IL-1F10 act as agonists or antagonists.
β-TREFOIL: THE STRUCTURE OF INTERLEU-KIN-1
All members of the IL-1 family adopt an all-β fold, the β−trefoil. Another cytokine family, the Fibroblast Growth Factors (FGFs), also adopts the same fold, indicating a structural relationship between the two families. The β−trefoil fold is also found in other diverse protein families from a variety of organisms and tissues including Kunitz trypsin inhibitors, actin-binding proteins, mannose receptors and plant cytotoxins. A classification of structural members of the IL-1 fold according to Structural Classification of Proteins (SCOP), [26] is presented in Table 1 . Despite the low sequence identity between representatives of each structural family, the structures of β−trefoil proteins can be readily superimposed within regions of secondary structure. In contrast, loops differ significantly among various β-trefoils.
The β−trefoil, first described by McLachlan [27] for soy bean trypsin inhibitor, is formed by twelve β−strands, creating five two-stranded hairpins. Two of the hairpins (strands 4, 5, 8, 9) with N-terminal strand 1 and C-terminal strand 12 form a six stranded barrel, Fig. (1) . The other three form a 'hairpin triplet' which caps one end of the barrel. The other end of the barrel is open. The interior of the barrel consists of three layers of packed residues, top (T), middle (M) and bottom (B), whose side chains fill the cavity, protruding from each barrel strand. The top layer is closer to the open end of the barrel, is partially exposed to solvent and displays low sequence similarity among the known β−trefoil structures. The middle and bottom layers contribute to the packing of the barrel core in strands 1, 5 and 9, and interface with the hairpin triplet (strands 4, 8 and 12) . Large hydrophobic residues occupy these positions. The hairpin-triplet strands pack in a triangular arrangement and six residues, one from each strand, pack against the core of the barrel, interlocking the triplet onto it. A total of 18 core residues have been identified in IL-1β [4] , [5] and are indicated in Fig. (1) . These hydrophobic residues have low solvent accessibilities and generally contact each other. While the sequence within β-strands is well conserved among IL-1 family members, major differences exist in the loops. Structural alignments reveal the above critical core positions have conserved amino acid polarity/hydrophobicity and it has been suggested that conservation in these residues is one of the defining features of the fold. However, sequence conservation is limited and often these positions are occupied by alternative amino acids with similar hydrophobicity, rather than identical ones. With distantly related β-trefoils these modifications become more extensive. Hence, β-trefoil proteins can perform diverse functions while maintaining their characteristic fold [5] . Thus it seems there are multiple ways of achieving the β−trefoil fold, rather than a unique way of packing, and there are significant differences in the way each protein achieves correct folding and packing of its core [5] .
In addition to the packing of hydrophobic side chains in the core positions of the structure, inter-strand interactions, which are often solvent-mediated, are crucial for the molecule's stability and "foldability". Recent mutation studies on strand 1 of human IL-1β show that residue substitutions affect the number of ordered water molecules within the barrel cavity and disrupt essential main-chain interactions in a highly organised network of hydrogen bonds [28] .
Another characteristic feature of this fold is that it is composed of three structural repeats (bbbLb: b for β−strand, L for long loop) of about 50 amino acids, whose similarity is not readily apparent from the sequence. However, structural alignment and superposition studies have enabled the detection of IL-1β internal pseudo-symmetry [4] .
The monomeric structural unit, the trefoil subunit, consists of a pair of anti-parallel β−sheets. The trefoil subunit has been identified as a monomeric structural element in epidermal growth factor (EGF), as an inserted domain in human type VI collagen, as a dimeric element in the protease inhibitor ecotine and in pancreatic lipase, and as a trimer in the β−trefoil fold [29] . It has been proposed that the β−trefoil structure has evolved through two successive gene duplication/fusion events. Selective pressure and evolutionary events have caused considerable divergence, despite the retention of the symmetric tertiary structure.
In the Kunitz inhibitor family, phylogenetic analysis shows that subunit III deviated much earlier than subunits I and II [29] . A phylogenetic tree, based on the multiple sequence alignment shown in Fig. (2) , shows that the IL-1β subunit I seems to be the most distant of the three Fig. (3) . In IL-1β, strands 6-10 (parts of trefoil subunits II and III, residues 65-120) and Phe42 (strand 4) form a folding intermediate, followed by folding of the remainder of the trefoil units III and I [30] . In Kunitz inhibitors, regions that show high variation (hypervariable regions) have been identified within the loops 2-3, 3-4, 4-5, 5-6, 7-8 and 8-9 [29] . The same loops show differences in sequence and length in the IL-1β multiple sequence alignment Fig. (2) .
Even though there is species-specific variation in gene organisation of IL-1β with varying number of exons and introns in each vertebrate species, the whole mature peptide is expressed by the final three exons of the transcript [11] . In fact, exon boundaries within the mature peptide can be aligned Fig. (2) . The final exon (exon 7 in mammals, exon 6 in chicken and catshark, exon 5 in seabass) encodes the terminal 5 β-strands of the trefoil, while exon 6 in mammals (exon 5 in chicken and catshark, exon 4 in seabass) encodes β-strands 4-7 of the trefoil. The first 3 β-strands together with a short stretch of around 15 residues containing the ICE cut site is encoded by exon 5 in mammals (exon 4 in chicken and catshark, exon 3 in seabass).
It has recently been shown that even if β−trefoil proteins display minimal sequence similarity, they are likely to form a single superfamily of proteins because they share common ancestry [31] . This brings the diverse protein families described in Table 1 together into a single group. This might be easily envisaged for other cytokines, such as FGF, but it is unexpected for proteins like cytotoxins and actin-binding proteins from plants, fungi (Dictyostelium) and invertebrate species to have the same fold [31] . Apparently, the structural framework is conserved, but changes in loop regions have conferred varying functions to members of the β−trefoil superfamily. Notably, all known β−trefoil proteins are involved in recognition [4] : Interleukin-1 family members are immune response mediators, fibroblast growth factors bind to cell surface receptors and induce mitosis, angiogenesis and chemotaxis, Kunitz inhibitors bind to proteases active sites, neurotoxins and lectins recognise and bind to cell surface carbohydrate moieties via their β-trefoil domains, hisactophilin and fascins are actin binding proteins. 
VERTEBRATE INTERLEUKIN-1β: SEQUENCE ANALYSIS
Recently, a number of vertebrate IL-1 sequences have become available and public databases now contain IL-1 sequences from cartilaginous and bony fish, amphibians, birds and a large number of mammalian sequences including marsupials and monotremes, the most ancient mammalian groups. More than 19 full-length IL-1β mammalian sequences are deposited. Many of the non-mammalian genes have been identified with homology cloning, but new techniques for the identification of remote homologues and the availability of whole genomes have enabled identification using only software tools [31] . The availability of these protein sequences allows a greater insight into the evolution of the IL-1 family and IL-1β in particular.
We have used CLUSTALW [32] to align all currently known non-mammalian mature IL-1β sequences from X. laevis [33] , chicken [34] , carp [35] , goldfish [36] , turbot [37] , halibut [38] , sea bass [39] , seabream [40] , red seabream [41] , trout [42] , [43] , leopard shark [44] and catshark [45] . We then made minor adjustments to remove gaps within strands and place them into loops. The resulting multiple alignment is shown in Fig. (2) . The three internal trefoil subunits are shown in three separate layers in this figure. A taxonomic classification of the fish species included in the alignment is shown in Table 2 . It can be seen that the phylogenetic tree clusters the vertebrate species in accordance to their taxonomic classification.
We find that within the mature peptides, overall sequence identity between fish and human sequences is around 35%. Between amphibians/birds and mammals it is 40/38.5%, while between possum (marsupial) -human it is 57% and platypus (monotreme) -human it is 48%. Higher mammalian sequences typically show 70% or greater sequence identity to human IL-1β. From the multiple sequence alignment, it is apparent that the greatest sequence similarity exists within the β-strands, while predicted loops connecting the β-strands show low sequence similarity. For instance between trout and human IL-1β, sequence identity within the β−strands is 48.2%, while for the whole mature protein is 38.2% (Table  3) . Loop length is generally not conserved across species.
Within the aligned fish species, the average sequence identity in barrel strands core positions (T, M, B) is 45%, while in the hairpin triplet core positions it is 78%. Sequence identity within only the M and B core barrel positions is 60%. Barrel strands, especially in the region close to the barrel rim (Top-T), are close to the surface and display greater variability. These residues are exposed to solvent and can be either polar or hydrophobic Fig. (1) .
More importantly, the M and especially the B residues of the barrel are well conserved. In strands 1, 5 and 9 there is a leucine, phenylalanine or other hydrophobic residues (isoleucine, valine, methionine), strand 1 being the most variable, while in almost all species, barrel strands 4, 8 and 12 at the bottom position have a phenylalanine (human: F42, F101, F146). Bottom residues from strands 4, 8 and 12 surround the barrel cavity and "pin" the hairpin triplet to the core of the barrel. They occupy equivalent positions in the pseudo 3-fold axis and although they are sequentially distant, they are juxtaposed in the tertiary structure. Mutation studies in these conserved positions (e.g. F->W) show that IL-1β can tolerate side-chain volume increases without significantly affecting stability, but such mutations affect folding kinetics [46] . Apparently, these residues are essential contacts in the transition state of the folding reaction.
The hairpin triplet core positions at strands 2 and 3 (trefoil subunit I), 6 and 7 (trefoil subunit II), and 10 and 11 (trefoil subunit III) are also occupied by large hydrophobic residues and are well conserved. In subunits I and II, the residue is usually a leucine. However, a few species differ especially in strand 2 (e.g. trout strand 2 has tryptophan). In subunit III, the core residue in strand 10 is an isoleucine except in cartilaginous fish, while the strand 11 core position is a valine, except for catshark which has an isoleucine.
It is apparent that in the core positions polarity/hydrophobicity is conserved in most of the vertebrate species. Less well-conserved core positions show variation between vertebrate superorders, but within each superorder usually a certain amino acid prevails. It is also notable that sequence conservation exists in only a small number of positions, which presumably stabilise the trefoil barrel and in the hydrophobic residues that interface the hairpin triplet to the barrel.
Although many non-mammalian IL-1β sequences have been published recently, structural information remains limited to human and murine IL-1β. These structures are very similar, but the murine sequence has a one residue deletion in loop 11-12. Superposition of the human and murine IL-1β (PDB codes 2I1B and 8I1B) backbones shows an RMS deviation of only 0.69Å. The main regions of structural differences are loops 2-3, 3-4, 4-5, 8-9 and 11-12. These loops are involved in receptor binding.
IL-1β PROCESSING: THE ICE CUT SITE
All identified vertebrate IL-1β proteins lack a signal peptide, suggesting that their secretion involves a nonclassical pathway. Processing of pro-IL-1β involves ICE (caspase 1), even though other proteases found in inflammatory fluids (e.g. granzyme A [47] , elastase, trypsin, chymotrypsin [48] , a mast cell chymase [49] , several matrix metalloproteinases [50] ) are capable of producing functional IL-1β. However, apart from mammalian sequences and a few other exceptions, there is generally no aspartic acid in the cut site region, and thus no apparent ICE cut site [51] . A multiple sequence alignment of the cut site region of several mammalian and all known non-mammalian vertebrate species is shown in Fig. (4) . Only mammals and turbot, halibut and at least one more bony fish (S Bird, personal communication) have an Asp within six residues upstream of the first strand of the β-trefoil (as predicted from the alignment). The recently identified IL-18 sequence from trout (J Zou, personal communication) and Japanese pufferfish (S Bird, Fig. (4) . Multiple sequence alignment of the CutSite region of vertebrate IL-1β. Mammalian IL-1β is cleaved by ICE (caspase 1) at the aspartic acid in bold. Non-mammalian sequences potential cutsites lack an Asp apart from turbot and halibut. In human IL-1β, elastase cleaves at A112-Y113 and granzyme A cleaves at R120. Regions of secondary structure (SecSt) are shown for the human IL-1β.
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personal communication) reveal a potential ICE cut site in both proteins. Predicted cut sites, Fig. (4) , have been used to produce recombinant 'mature' IL-1β which has been shown to be active in trout [52] , as well as in chicken [34] and carp [53] . Caspases have been cloned from various fish species and chicken, suggesting that members of this family are present in all vertebrates [11] . However, the lack of an Asp in the cut site region of most of the non-mammalian vertebrate IL-1β residue suggests that other enzymes may also be implicated in the processing of pro-IL-1β in vertebrates.
IL-1R BINDING
Binding of IL-1α or IL-1β to the IL-1RI is an early step in IL-1 signal transduction. Full signal transduction requires the recruitment of another IL-1R like protein, IL-1RAcP. Analysis of the crystal structures of human and murine IL-1β, human IL-1α, IL-1RA, IL-1β/IL-1RI and IL-1RA/IL-1RI, as well as extensive mutagenesis studies have established that the agonist molecules bind to IL-1R in two sites, A and B, Fig. (5) . Binding to both sites is essential to trigger a biological response. The antagonist molecule binds to site A only, therefore occupying the receptor molecule without activating it, thus providing another level of control of signal transduction [54] . This mode of receptor binding is structurally unique among the known cytokine-receptor complexes. IL-1β agonists bind to the receptor in such a way that the uncapped end of the barrel is presented to domain III of the receptor, while the side of the barrel and part of the hairpin triplet is presented to domains I and II, Fig. (5) . Domains I and II of the receptor are tightly associated with three salt bridges, hydrophobic side chain interactions and a disulphide bond that connects domain I with the short linker between domains I and II. Domain III is linked via a longer 7-residue flexible linker, the "hinge" region, allowing for great flexibility. The IL-1β structure does not significantly change upon binding [54] , but domain III of the receptor is tilted by 20 o compared to the IL-1RA/IL-1RI complex. Domain III of the receptor associates strongly with IL-1 agonists and its structural conformation is critical in determining agonist/antagonist activity by inducing binding of the accessory protein and activation [55] . The free and receptor bound IL-1β backbones differ by 0.76Å RMS, mainly in the loops involved in receptor binding. IL-1RA binds to the type I receptor more intimately than IL-1α or IL-1β [55] . On the other hand, the type II "decoy" receptor binds agonists with higher affinity than IL-1RA in the following order: IL-1β, proIL-1β, IL-1α, IL-1RA [1] .
The discovery of IL-1R Toll-like receptor family members, such as trout IL-1R types I [56] and II [57] , salmon IL-1RI [58] , IL-1RAcP [59] and ST2 [60] , will allow modelling of ligand-receptor interactions and identification of residues critical for complex formation in each species.
Receptor Binding Site A
Receptor binding site A is common to all IL-1 proteins and makes contact with domains I and II of IL-1RI. In the human complex it comprises the residues listed in Table 4 , the most important of which are Arg11, Gln15, His30 and Gln32. The first two bind to domain II of the receptor, while the latter associate within the deep pocket between domains I and II [54] . Within the ligand, site A spans mostly regions of the trefoil subunit I (strands 1, 2, 3 and loops 1-2, 2-3, and a large part of loop 3-4) that associate with domain II and the cleft between domains I and II of the receptor, and trefoil subunit III (loop 10-11, strands 11 and 12) that bond mostly to domain I of the receptor. The overall sequence identity in vertebrate IL-1β in site A is 28%. Most of the positions display less than 30% identity, with the exception of Leu31 which is universally conserved in all species. Its side chain is oriented towards the loop interior and presumably plays a role in stabilising the optimal loop conformation, and allowing the neighbouring residues His30 and Gln32 to interact with the receptor. Other human IL-1 family members, such as IL-1α, IL-1RA, IL-1F5, 6, 7, 8, 9 also have Leu at position 31, while other β-trefoils e.g. FGF differ in this position. 
Sequence identity is categorised as follows: <30%, low; 31-65%, medium; >66% high. Overall sequence identity among vetebrate IL-1β sequences (Figure 1 ) is 28%. The total ligand buried surface is 1,087A 2 . Site A has 10 salt bridges and 7 hydrogen bonds. The location of residues within strands is denoted by 's' followed by the number of the strand. Residues in loops are denoted by the numbers of the flanking strands.
All bony fish species have an insertion in loop 2-3 relative to the human sequence that ranges between one (acanthopterygii: turbot, sea bass; protacanthopterygyii: trout) and five residues (ostariophysi: carp, goldfish), which may suggest more extensive interactions with the strands of domain II of the bony fish receptors. This insertion is not found in cartilaginous fish, but exists in platypus (monotreme) and xenopus (amphibian) ( Table 3) . Cartilaginous fish have a two amino acid deletion within the long loop connecting strands 3-4, which is buried in the cleft between domains I and II of the receptor. Notably, human IL-1α has a two residue deletion in this region. Trout IL-1β has a two residue insertion in loop 10-11 and it may form more extensive associations in this area. Identification of trout receptors IL-1R types I [56] and II [57] , will allow more detailed study of these ligand-receptor interactions.
Receptor Binding Site B
IL-1's receptor binding site B contacts only domain III of the receptor. The IL-1β residues involved in Site B binding are shown in Table 5 . A number of hydrophilic residues near the open end of the barrel interact with residues of complementary charge/polarity in domain III of the receptor. In the human complex, most of the binding energy depends on hydrophobic and hydrophilic interactions. Site B includes residues from all three trefoil subunits. Extensive contacts are made in residues located at the N-terminus of the mature peptide and the first residues of strand 1, loop 4-5, loop 7-8, strand 8 and the C-terminal region. In total the aligned sequences of Fig. (2) show sequence identity of 21% within Site B, which is lower than in site A. However, Lys103 at barrel strand 8 is very well conserved (71%). This residue lies in the middle (M) position of this particular barrel strand and in vertebrate IL-1β sequences it is consistently basic (lysine/arginine) and is involved in site B binding. However, other β−trefoils have a hydrophobic amino acid in the corresponding position, Figs. (1) and (2).
Bony fish, cartilaginous fish, as well as amphibians, birds and lower mammals have insertions relative to the human protein in loop 4-5 that range in length from one (most fish) to five (chicken) amino acids. It is interesting that this region has been characterised as a "trigger region", since it is missing in IL-1RA (6 residue deletion), Table 3 . Moreover, all fish have a 2-4 amino acid insertion between strands 7 and 8. Human and murine IL-1β have a cis-proline followed by a stretch of three charged residues (lysines in human) that interact with a complementary charged receptor region [54] . However, this proline residue is not conserved in nonmammals suggesting that the loop between strands 7-8 adopts a different geometry and forms alternative interactions with domain III of the corresponding receptor. Fish have a smaller one or two residue insertion between strands 8-9. This loop contacts the "hinge" connecting domain III of the receptor to domains I/II. Binding in this region could help stabilise domain III in the correct orientation for subsequent high affinity association of IL-1RAcP. Thus it seems that the mode and extent of binding between IL-1β and its receptor varies between vertebrate groups and species.
IL-1RAcP Binding
Extensive mutagenesis studies have identified certain IL-1β mutants with intact or minimally reduced receptor binding affinity, while showing 10-to 100-fold reduced biological activity as determined by lymphocyte proliferation and the induction of prostaglandin PGE2 in fibroblasts. These findings indicate that receptor binding and biological activity are at least in part separate, and that binding of IL-1β to the receptor is necessary, but by itself insufficient, for exerting biological activity [61] . For example, binding of antibodies against regions at domains II and III of IL-1RAcP inhibit complex formation with IL-1RI, but not receptor binding [16] . The mutated residues are located in areas distinct from the receptor binding sites A and B. A list of the mutations is given in Table 6 and their locations are indicated in Figs. (2) and (5). More recently, a preliminary model of the IL-1β/IL-1R complexed with IL-1RAcP has been presented [62] . According to this model, IL-1RAcP contacts the "back" of IL-1RI wrapped around IL-1β and with parts of IL-1β itself, close to the actual receptor binding sites. The above-mentioned IL-1β mutations are located on the surface of the molecule and are in proximity to IL1RAcP. They form two faces, one from each side of the long axis of the IL-1R/IL-1β complex. Overall, the sequence identity at these positions is 32%. Thus, as in the case of sites A and B, there is sequence variation between vertebrate superorders, while closely related species may share a common residue.
Fish With More Than One IL-1β Gene
In some fish species e.g. carp, goldfish and trout, two IL-1β genes have been isolated [43] . Carp and goldfish belong taxonomically to the same order (Cypriniformes). The two IL-1β proteins are 80% identical in each fish species. Sequence variations exist in three core structural positions, but any substitutions are often conservative. More variation is apparent in positions that, according to sequence similarity to the human, are involved in receptor binding site B. In three positions, each variant shares the same residue in both species. These variants might display differential affinities to the receptor, thus regulating IL-1β function. In phylogenetic trees, carp IL-1β1 and goldfish IL-1β1 form one group, and carp IL-1β2 and goldfish IL-1β2 form a second group (data not shown). Moreover, the variants differ in sequence, again relative to human, in three positions that might be involved in IL-1RAcP binding, hinting at differential affinities to IL1RAcP. For the case of the two trout IL-1β, sequence variation is observed in 5 positions within site A and in 10 positions within site B. Identification of IL-1RAcP sequences from fish [59] , combined with protein modelling techniques may help elucidate the details of IL-1β/IL-1R/IL-1RAcP complex formation in each species and its effects on biological activity.
IL-1β PEPTIDES WITH AGONIST/ANTAGONIST ACTIVITY
IL-1β derived peptides with agonist or antagonist activity have been a focus of interest because of their potential pharmaceutical application. Despite extensive efforts, identification of high affinity small molecule cytokine receptor agonists or antagonists has proven to be a difficult task.
Antoni et al. [6] identified a nonamer within the loop between strands 4 and 5 with agonist properties, Figs. (2) and (6) . This peptide demonstrates immunostimulatory characteristics, but it lacks the full repertoire of biological function displayed by native IL-1β. By screening recombinant peptide libraries, Yanofsky et al. [69] identified a high affinity antagonist peptide that binds specifically to human IL-1RI. Vigers et al. [70] solved the crystal structure of this 21 amino acid peptide (AF10847) bound to IL-1RI (PDB code: 1G0Y). Interestingly, even if the peptide binds to the same binding site as IL-1RA and IL-1β, its structure is distinct and unrelated to the naturally occurring ligands. The middle part of the peptide forms a helix and binds to the IL-1RI domain I/II junction (site A), while the terminal regions form strands that interact with domains I and II of the receptor (site A). Comparing the receptor domain conformations between the IL-1β/IL-1RI and AF10847/IL-1RI complexes shows a 170 o rotation of domain III. This places site B facing away from the ligand and puts the C-terminus very close to the N-terminus in domain I. Additionally, domain I is rotated 5 o with respect to domain II [70] .
Using sequence alignments, Peddie et al. [7] designed two trout IL-1β derived peptides. The first, P1, corresponds to the agonist nonamer identified by Antoni et al. [6] , while the second P3, a decamer, maps to the loop connecting 
Sequence identity is categorised as follows: <30%, low; 31-65%, medium; >66% high. Overall sequence identity among vetebrate IL-1β sequences (Figure 1 ) is 21%. The total ligand buried surface is 1,001A 2 . Site B has 13 salt bridges and 7 hydrogen bonds. The location of residues within strands is denoted by 's' followed by the number of the strand. Residues in loops are denoted by the numbers of the flanking strands. strands 8 and 9. Peptide P3 induces head-kidney leukocyte migration, while peptide P1 had no effect when used alone. However, a combination of peptides P1 and P3 produces a synergistic effect on binding, suggesting that IL-1R complexes with P3 until it becomes limiting and then binds P1 in a different region [7] . Both loops 4-5 and 8-9 are involved in site B binding. Loop 4-5 is one of the areas of the molecule important for agonist activity and associates with domain III, and is also known as the trigger region [10] . Loop 8-9 binds to the linker that connects domains II and III and helps maintain a certain configuration of domain III that seems to be essential for signal transduction. The crystal structure of IL-1RI bound to AF10847 demonstrates this flexibility, even though it is unknown whether that configuration exists in physiological conditions or is an artefact of the crystallisation process [70] .
The lack of agonist activity of P1 itself in trout can be explained on the basis of low sequence similarity between trout and human IL-1β within the binding sites, and due to their potentially different mode of binding to their receptors [42] . As shown in Table 3 , trout IL-1β has a two amino acid insertion in loop 4-5 and a single residue insertion in loop 8-9, thus suggesting that although the same regions are implicated in receptor binding, the interactions and the configuration of the loops differ. It may be that in trout the associations between P3 and the receptor, which are likely to be in the linker region between domains II and III, can occur readily and result in a functional orientation of the complex. The P1 binding site may then become exposed and allow the recruitment of P1 as well in to the complex.
IL-1 AS A PHARMACEUTICAL TARGET
Recently, significant progress has been achieved in the understanding of autoimmune disease and inflammation. By applying this knowledge, a collection of biological agents has been designed to interfere with selected stages of the immune or inflammatory response. One of the main drug targets has been the IL-1 system. IL-1β affects a variety of cells, usually in conjunction with Tumour Necrosis Factor alpha (TNFα). These two molecules have attracted special attention because of their pro-inflammatory properties and their role in various diseases. Inhibition of these cytokines in patients with rheumatoid arthritis (RA) using antagonists improved their clinical status. However, a large proportion of 
Sequence identity is categorised as follows: <30%, low; 31-65%, medium; >66% high. Overall sequence identity among vetebrate IL-1β sequences (Figure 1 ) is 32%. The location of residues within strands is denoted by 's' followed by the number of the strand. Residues in loops are denoted by the numbers of the flanking strands.
patients did not respond to these agents, hinting that the pathophysiology of RA involves further mediators [71] , [72] . IL-1 has a central role in controlling immune and inflammatory responses and this is highlighted by the fine balance between under-expression and over-expression. The tight regulation of the IL-1 pathway may reflect this. On one hand, IL-1 can help boost immune responses and function as an adjuvant. For example, administration of IL-1β has been investigated for potential use as a vaccine adjuvant in the treatment of influenza. However, as IL-1β is a pro-inflammatory agent, the balance between clinical benefit and toxicity is very narrow. On the other hand, antagonists of IL-1 activity are useful in several inflammatory conditions, such as RA and osteoarthritis. For example, IL-1 plays an important role in pathophysiology of RA because it stimulates the recruitment of inflammatory cells within the affected joints promoting catabolism of cartilage by decreasing the synthesis of proteoglycans and increasing the expression of matrix metalloproteinases [73] .
Binding of IL-1 is the first step on the activation of IL-1R and signal transduction. Therefore, several potential drugs have targeted this interaction. However, targeting the IL-1 system requires careful consideration of its unique features. For example, IL-1 activity is tightly regulated at several levels and some aspects of the IL-1 regulation system thus far remain unique and include: (i) the need for processing into a functional mature peptide (IL-1β); (ii) the presence of a naturally occurring receptor antagonist, with similar overall structure and higher affinity to the type I receptor than the agonists; (iii) its highly effective receptor system -e.g. less than 10 IL-1 molecules/cell stimulate a full biological response [9] ; (iv) the presence of circulating soluble receptors and decoy receptors with higher affinity to agonists; (v) the recruitment of another molecule, IL-1RAcP, to form a tertiary complex, essential for triggering activation.
Even though several agents have been tested in clinical trials, the first and so far only commercial drug that targets the IL-1 system is anakinra (Kineret®, Amgen, Thousand Oaks, CA). This is a recombinant non-glycosylated IL-1 receptor antagonist isolated from human monocytes and expressed in E.coli [73] . It was approved in 2001 for the treatment of RA in combination with methotrexate. Administration of anakinra improved clinical parameters of disease activity and thus provides a strong base for development of alternative strategies aiming to inhibit the effects of IL-1 in arthritis.
Soluble IL-1RII has also been investigated as a candidate drug in clinical trials. Theoretically, receptors are ideal natural drugs for the treatment of diseases caused by IL-1. However, inherent disadvantages have hindered their progress as drugs. For example, they are potentially immunogenic to patients and have a short half-life because they are metabolised by peptidases and proteases. Moreover, soluble IL-1R act as a "sink" not only for IL-1, but also IL-1RA, which is a potent anti-inflammatory agent. As a result, the dose must be high enough to reimburse the binding of IL-1RA. Otherwise, administration of IL-1R might enhance inflammation as a side-effect.
An alternative therapeutic approach to treat inflammatory conditions is to inhibit the processing and secretion of IL-1β.
This may be achieved with ICE inhibitors. However, ICE is not involved in processing of IL-1α, which can still exert its biological functions. Moreover, as mentioned above, several other proteolytic enzymes are capable of processing IL-1β in the absence of ICE [17] .
Another promising candidate currently in phase II clinical trials for treatment of RA is the "IL-1 trap". This is a fusion protein containing parts of the extracellular regions of IL-1RI and IL-1RAcP engineered into a single chain, with two of these chains coupled to the Fc region of human IgG1 to form a dimer. The IL-1 trap is synthesised as a recombinant protein by cultured eukaryotic cells. It has a strong binding affinity for both IL-1 agonists, which compare favourably to monoclonal antibodies. Although IL-1RI binds IL-1RA with higher affinity than IL-1β, the IL-1RAcP component of the trap reverses the relative affinities, so that it binds IL-1β more tightly than IL-1RA [74] .
CONCLUSION
Identification of IL-1 family members in species as ancient as cartilaginous fish has established the presence of this cytokine group across vertebrates. Today, the presence of IL-1 has been reported in all vertebrate classes except reptiles. Apart from IL-1β, several other IL-1 members have been discovered in fish: IL-18 [75] , IL-1RA and at least one more yet unidentified IL-1 family member in trout (S Bird, personal communication). Analysis of multiple sequence alignments has shown that the characteristic β-trefoil structure is maintained across vertebrate IL-1, and that the structurally important features are conserved. Despite the structural similarity, with the exception of three bony fish, all other non-mammalian IL-1β sequences discovered so far lack an ICE cut site, so their processing mechanism remains unclear. On the other hand, two IL-18 sequences from bony fish possess an ICE cut site. Recombinant IL-1β production from vertebrate species will determine experimentally the length of the biologically active mature peptides.
A number of IL-1R Toll-like receptors including IL-1RI, IL-1RII, IL-1RAcP, IL-18R and ST2 have been recently discovered in salmon, trout and Japanese pufferfish, which will allow study of species-specific ligand receptor interactions. Initial observations show clear sequence similarity between mammalian and fish receptors and the same overall structure, while most of the differences are located in the loops that interact with the ligand. Each species has evolved its own unique way of binding through ligand-receptor coevolution. This is evident in loops of the ligand that are involved in receptor binding, which display length and sequence variations that suggest alternative associations between ligand and receptor, while the structural frame of the core of the molecule is conserved. We expect that modelling studies, using existing human and murine structures as templates will facilitate identification and detailed mapping of these interactions.
A peptide derived from trout IL-1β has been shown to possess agonist activity [7] . This is derived from a different region of the molecule from the one identified by Antoni et al. [6] that has been known to display agonist activity in human. Peptide research may further identify the regions on IL-1 responsible for agonist and/or antagonist activity and it will be interesting to examine whether these are conserved across vertebrates.
Evolutionary analysis of IL-1-receptor interactions and mutagenesis studies may prove useful in the prediction of IL-1 function in vertebrate species, and in helping to identify significant sequence and structural elements and receptor interactions. Knowledge about the β-trefoil fold determinants may allow the design of novel engineered IL-1 with enhanced potency, stability, and the desired agonist or antagonist features. Genetic engineering of loops utilising features from other species may convey new improved features to the original protein. More importantly, evolutionary analysis of the IL-1 system may also indicate new avenues for therapeutic intervention. 
